Prelude Therapeutics (PRLD) Cash from Operations (2019 - 2026)
Prelude Therapeutics (PRLD) posted Cash from Operations of 21685000.0 for Q1 2026, down 193.8% sequentially from 23119000.0 in Q4 2025, and up 36.65% YoY from 15868893.58 in Q1 2025.
Prelude Therapeutics (PRLD) Cash from Operations (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Cash from Operations for 8 years, with the latest figure at 21685000.0 in Q1 2026.
- Quarterly Cash from Operations rose 36.65% year-over-year to 21685000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43756000.0 (up 58.46% YoY) and the FY2025 annual result came in at 56302000.0, up 45.28% from the prior year.
- Cash from Operations eased to 21685000.0 in Q1 2026 per PRLD's latest filing, from 23119000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 23119000.0 in Q4 2025 and troughed at 34231000.0 in Q1 2025.
- A 5-year average of 21862764.71 and a median of 23057000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations sank 49.82% in 2023, then jumped 211.45% in 2025.
- Over 5 years, Cash from Operations stood at 22927000.0 in 2022, then fell by 2.84% to 23578000.0 in 2023, then advanced by 12.02% to 20744000.0 in 2024, then surged by 211.45% to 23119000.0 in 2025, then sank by 193.8% to 21685000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 21685000.0, 23119000.0, and 19115000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | -15.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.57 Mn |
| Jun 30, 2026 | -15.57 Mn |
| Mar 31, 2026 | -21.69 Mn |
| Mar 31, 2026 | -21.69 Mn |
| Dec 31, 2025 | 23.12 Mn |
| Dec 31, 2025 | 23.12 Mn |
| Sep 30, 2025 | -19.12 Mn |
| Sep 30, 2025 | -19.12 Mn |
| Jun 30, 2025 | -26.08 Mn |
| Jun 30, 2025 | -26.08 Mn |
| Mar 31, 2025 | -34.23 Mn |
| Mar 31, 2025 | -34.23 Mn |
| Dec 31, 2024 | -20.74 Mn |
| Dec 31, 2024 | -20.74 Mn |
| Sep 30, 2024 | -27.30 Mn |
| Sep 30, 2024 | -27.30 Mn |
| Jun 30, 2024 | -23.06 Mn |
| Jun 30, 2024 | -23.06 Mn |
| Mar 31, 2024 | -31.79 Mn |
| Mar 31, 2024 | -31.79 Mn |